All Oncology News

Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.

The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

The FDA has issued an alert that evidence from the phase 3 OCEAN study of melphalan flufenamide, which was recently approved for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma, has indicated that the doublet resulted in an increased risk of death in this population.

Lakshmanan Krishnamurti, MD, has been named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant at Yale New Haven Children’s Hospital and Leader of the Smilow Cancer Hospital Pediatric Hematology/Oncology Program.

Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull.

The IDH2 inhibitor enasidenib demonstrated promising efficacy in combination with azacitidine and as a single agent in patients with high-risk, IDH2-mutated myelodysplastic syndrome.

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk myelodysplastic syndrome.

The method used to calculate how obesity is measured may impact whether it should be considered as a risk factor for non–small cell lung cancer.

Doublet and triplet chemotherapy-based therapies are standard treatment options for patients with BRAF V600–mutant metastatic colorectal cancer.

It is difficult to dispute that these are troubling times for government officials and public health agencies.

Joseph W. Kim, MD, Associate Professor of Medicine at Yale Cancer Center, has received a 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

Leslie L. Montgomery, MD, and Tara M. Balija, MD, discuss the benefits of a novel reflector device in patients with breast cancer, its efficacy in identifying clipped axillary lymph nodes, and the potential future use of this device in other cancer types.

Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing indications.

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

As the State’s only NCI-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey will lead this effort.

Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

The net effect of the Oncotype DX Genomic Prostate Score in patients with favorable-risk prostate cancer was to move away from active surveillance, altering the understanding of how prognostic molecular assays that generate probabilities of poor outcome can impact treatment decisions in diverse populations.

Racial minorities with limited-stage small cell lung cancer, including African American and Asian patients, were found to have more favorable survival outcomes compared with White patients, which suggests that race is associated with survival in this disease.

The addition of pembrolizumab to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival vs chemotherapy alone in patients with metastatic triple-negative breast cancer whose tumors had a PD-L1 expression of a combined positive score of 10 or higher, meeting the primary end point of the phase 3 KEYNOTE-355 trial.

The FDA has approved pembrolizumab for the treatment of patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 therapy.

More than 50 health care professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, the American Society for Radiation Oncology, the Society for Gynecologic Oncology, and the American Medical Association issued a joint statement Monday calling for all health care employers to require COVID-19 vaccinations for all their employees.